Insider Transactions in Q1 2022 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,420
-1.0%
|
$39,760
$28.17 P/Share
|
|
Mar 28
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.4%
|
$14,672
$28.17 P/Share
|
|
Mar 24
2022
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,055
+28.4%
|
-
|
|
Mar 24
2022
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
33,875
+19.24%
|
-
|
|
Mar 24
2022
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
19,934
+13.14%
|
-
|
|
Mar 24
2022
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
19,428
+38.4%
|
-
|
|
Mar 24
2022
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
19,428
+36.11%
|
-
|
|
Mar 23
2022
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,454
-10.29%
|
$471,258
$27.03 P/Share
|
|
Mar 23
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,167
-3.7%
|
$112,509
$27.03 P/Share
|
|
Mar 23
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,452
-2.14%
|
$66,204
$27.03 P/Share
|
|
Mar 21
2022
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
7,224
+4.08%
|
$195,048
$27.69 P/Share
|
|
Mar 21
2022
|
Patrick D Walsh Director |
BUY
Open market or private purchase
|
Direct |
5,000
+8.56%
|
$135,000
$27.76 P/Share
|
|
Mar 21
2022
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.26%
|
$135,000
$27.87 P/Share
|
|
Mar 19
2022
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,346
+50.0%
|
-
|
|
Mar 18
2022
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.27%
|
$135,000
$27.15 P/Share
|
|
Mar 17
2022
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Open market or private purchase
|
Indirect |
5,000
+50.0%
|
$135,000
$27.65 P/Share
|
|
Mar 17
2022
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Open market or private purchase
|
Direct |
5,000
+21.31%
|
$135,000
$27.65 P/Share
|
|
Feb 15
2022
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-9.04%
|
$46,680
$40.25 P/Share
|
|
Feb 15
2022
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-7.34%
|
$47,360
$40.25 P/Share
|